Log In
Print
BCIQ
Print
Print this Print this
 

BPX-201

  Manage Alerts
Collapse Summary General Information
Company Bellicum Pharmaceuticals Inc.
DescriptionGenetically modified, autologous dendritic cells targeting prostate cancer cells
Molecular Target Prostate-specific membrane antigen (PSMA) (FOLH1) (GCPII)
Mechanism of ActionVaccine
Therapeutic ModalityActive immunotherapy
Latest Stage of DevelopmentPhase I
Standard IndicationProstate cancer
Indication DetailsTreat metastatic castration-resistant prostate cancer (CRPC)
Regulatory Designation

Partner


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today